CURX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

CURX ▲ +4.79% at T+5d

NEUTRAL call ✓ call won +4.79% · α vs SPY +5.51% · entry $0.3130 → $0.3280

Next anchor: T+20d in 2d

Last close $0.3050 (close Jun 8) · -2.56% from $0.3130 entry

Entry anchored
May 13, 01:51 PM ET
via Databento tick

T+1d

-4.15%

call -4.15% · α -2.93%

$0.3000

settled 26d ago

T+5d

+4.79%

call +4.79% · α +5.51%

$0.3280

settled 20d ago

T+20d

—

call — · α —

—

in 2d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Curanex Pharmaceuticals provided a Q1 2026 business update focused on preclinical progress for its lead candidate Phyto-N (ulcerative colitis), including completion of GMP pilot-scale manufacturing and a dose-range finding toxicology study with no adverse findings. The company also expanded its pipeline strategy to include cancer cachexia. With only $4.0M in cash and no revenue, the filing is a routine development-stage update with no financial results or guidance — the stock's $9M market cap and historical negative drift suggest limited near-term catalyst impact.

Actionable Insight

Monitor for IND submission timing and any financing events (dilutive offering likely given $4M cash burn). The cancer cachexia expansion is early-stage and non-catalytic. Historical T+20 drift on CURX is negative — avoid directional positioning until a concrete catalyst (IND acceptance, partnership, or financing) materializes.

Key Facts

Completed GMP pilot-scale batch of Phyto-N in February 2026
Completed 28-day dose-range finding toxicology study with no treatment-related adverse findings
Expanded pipeline to include cancer cachexia as a new core indication
Cash and cash equivalents of $4.0M as of March 31, 2026
Planned IND submission for ulcerative colitis in Q4 2026
No revenue reported; pre-revenue clinical-stage biotech

Financial Impact

No revenue or earnings reported; cash position of $4.0M provides runway for IND-enabling activities but limited capital for extended operations

cash

Risk Factors

Cash runway limited to $4.0M — likely need for dilutive financing before Q4 2026 IND
Pre-revenue stage with no approved products; regulatory and clinical failure risk
Historical negative drift on CURX filings suggests limited market interest in development updates

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3294973

5 reports for CURX

T+1T+5T+20T+60

Filters

Reports for CURX — sortable, filterable
	Type				Now
May 14, 2026 26d ago	8-K NEUTRAL ★ 3/10	$0.3130 $0.3280	▲ +4.79%	▲ +5.51%	$0.3050 (−2.56%)
May 14, 2026 26d ago	Press Release NEUTRAL ★ 3/10	$0.3130 $0.3280	▲ +4.79%	▲ +5.51%	$0.3050 (−2.56%)
May 7, 2026 4w ago	8-K NEUTRAL ★ 5/10	$0.3160 $0.3150	▼ −0.32%	▼ −1.82%	$0.3050 (−3.48%)
Apr 2, 2026 9w ago	8-K NEUTRAL ★ 3/10	$0.4900 $0.4640	▼ −5.31%	▼ −8.93%	$0.3050 (−37.76%)
Mar 30, 2026 10w ago	Press Release NEUTRAL ★ 3/10	$0.5110 $0.4440	▼ −13.11%	▼ −17.06%	$0.3050 (−40.31%)

US Market Status

Market Closed — Opens in 7h 11m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access